MedTrace Logo

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

NCT00713193 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-05-03

Study results available
· View outcomes & findings →

Summary

This research involves the use of immune base therapy as an adjunct to plasma exchange, the present standard of care for thrombotic thrombocytopenic purpura (TTP). Funding source -FDA OOPD

Conditions

  • Thrombotic Thrombocytopenic Purpura

Interventions

DRUG

Cyclosporine

2-3 mg/kg orally in a twice day divided dose for 6 months

DRUG

Prednisone

1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.

Sponsors & Collaborators

  • Food and Drug Administration (FDA)

    collaborator FED

  • Ohio State University

    lead OTHER

Principal Investigators

  • Spero R Cataland, MD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2017-09-20
Completion
2017-09-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00713193 on ClinicalTrials.gov